BDTX (STOCKS)
Black Diamond Therapeutics, Inc. Common Stock
$2.720000
+0.160000 (+6.25%)
Prev close: $2.560000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Mark A. Velleca
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $155.25M
- Employees
- 54
- P/E (TTM)
- 6.59
- P/B (TTM)
- 1.30
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.27 | $-0.19 | -0.0800 | -42.11% |
|
Sep 2025 (Q3)
|
$-0.15 | $-0.24 | +0.0893 | +37.32% |
|
Jun 2025 (Q2)
|
$-0.19 | $-0.25 | +0.0616 | +24.48% |
|
Mar 2025 (Q1)
|
$0.98 | $0.02 | +0.9583 | +4,416.13% |
Financial Statements
| Revenues | $70.00M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $57.48M |
| Nonoperating Income/Loss | $9.85M |
| Operating Expenses | $57.48M |
| Research and Development | $33.56M |
| Other Operating Expenses | $23.92M |
| Operating Income/Loss | $12.52M |
| Income/Loss From Continuing Operations After Tax | $22.37M |
| Income/Loss From Continuing Operations Before Tax | $70.00M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | $22.37M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $22.37M |
| Net Income/Loss Available To Common Stockholders, Basic | $22.37M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.39 |
| Diluted Earnings Per Share | $0.39 |
| Basic Average Shares | 56,868,111 |
| Diluted Average Shares | 57,562,746 |
| Assets | $143.01M |
| Current Assets | $132.44M |
| Noncurrent Assets | $10.57M |
| Fixed Assets | $365.00K |
| Other Non-current Assets | $10.21M |
| Liabilities | $30.80M |
| Current Liabilities | $15.73M |
| Accounts Payable | $579.00K |
| Wages | $2.92M |
| Other Current Liabilities | $12.23M |
| Noncurrent Liabilities | $15.07M |
| Commitments and Contingencies | $0.00 |
| Equity | $112.21M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $112.21M |
| Liabilities And Equity | $143.01M |
| Net Cash Flow From Operating Activities | $29.61M |
| Net Cash Flow From Operating Activities, Continuing | $29.61M |
| Net Cash Flow From Investing Activities | -$44.91M |
| Net Cash Flow From Investing Activities, Continuing | -$44.91M |
| Net Cash Flow From Financing Activities | -$146.00K |
| Net Cash Flow From Financing Activities, Continuing | -$146.00K |
| Net Cash Flow | -$15.44M |
| Net Cash Flow, Continuing | -$15.44M |
| Comprehensive Income/Loss | $22.44M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $22.44M |
| Other Comprehensive Income/Loss | $22.44M |